Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia
ConclusionPopulation targeting using mutation testing forTP53 andIGHV when performed with del(17p) testing specifically in the context of frontline ibrutinib choice does not make a cost-ineffective treatment into a cost-effective treatment.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Australia Health | Chronic Leukemia | Chronic Lymphocytic Leukemia | Economics | Genetics | Health Management | Leukemia | Rituxan | Study